207, Porter St

Boston,

MA,

USA,

ZIP: 02128

Phone: +16174554188

The brand-new Targeted Radiopharmaceuticals US Summit (TRP US) is the only industry-led meeting dedicated to the development of next-generation radioligands. The TRP sector has developed dramatically over the previous 18 months, with a wave of new investment in light of Lutathera's extraordinary performance.

Are you part of a pharmaceutical business aiming to have their Theranostic approved? If so, this agenda is designed to deliver you a well-rounded and complete understanding of the fast-paced radiopharmaceutical sector while also learning about the critical function of diagnostic imaging.

Hear the latest insights, case studies, and novel data to help accelerate the development of next-generation radioligand therapies from clinical approval to commercialization. This is the only in-person meeting to bring the discussion around the challenges and opportunities facing developers of Theranostic radioligand therapies.

URLs:
Tickets: https://go.evvnt.com/1065196-2?pid=1052
Brochure: https://go.evvnt.com/1065196-3?pid=1052

Prices:
Drug Developer Pricing - Conference + 2 Workshops: USD 4197.0,
Drug Developer Pricing - Conference + 1 Workshop: USD 3598.0,
Drug Developer Pricing - Conference Only: USD 2999.0,
Standard Pricing - Conference + 2 Workshops: USD 5197.0,
Standard Pricing - Conference + 1 Workshop: USD 4498.0,
Standard Pricing - Conference Only: USD 3799.0

Sarah Cheal, Assistant Professor, Weill Cornell Medical College, Alan B. Packard, Sr. Research Associate/Associate Professor, Boston Children's Hospital/Harvard Medical School, Stanley Satz, Chairman, Advanced Innovative Partners, Jarrod Longocor, Chief Business Officer, Cellectar Biosciences, Shaemus Gleason, Executive Vice President, Clarity Pharmaceuticals, Jason Dearling, Senior Director, Radiopharmacology, Curie Therapeutics, Kemp Dolliver, Senior Analyst/ Director of Research, Brookline Capital Markets, Chris Leamon, Chief Scientific Officer Fusion Pharmaceuticals, Fusion Pharmaceuticals, Peter Conti, Professor of Radiology PET Imaging Center and Director, Molecular Imaging Center, Keck School of Medicine, Manuel Bardies, Cancer Research Institute, Montpellier, France, Jason Hurt, Chief Medical Officer, Oranomed, Alexander Yordanov, Senior Radiochemist and Tech Service Lead, Progenics Pharmaceuticals, Inc., Riccardo Canevari, Managing Director and Chief Executive Officer, RadioPharm Theranostics, John Babich, President and CEO, Ratio Therapeutics, Roland Turck, Managing Partner, TurckBio, Amos Hedt, Chief Business Strategy Officer, Viewpoint Molecular Targeting, Inc, Kelly Orcutt, Senior Principal Scientist, Viewpoint Molecular Targeting Inc, Mengshi Li, Principal Scientist, Viewpoint Molecular Targeting, Inc., Geoffrey Johnson, Nuclear Medicine Specialist, Radiologist, Mayo Clinic, Luke Nordquist, Medical Oncologist and CEO/Founder, XCancer Research, Ken Song, Chairman of the Board and Founder, Rayze Bio, Oliver Sartor, Laborde Professor for Cancer Research, Medical Director Tulane Cancer Center, Associate Dean for Oncology, Tulane Medical School